Deals, Partnering

Asset purchase agreement for stem cell reagent and services business unit

Posted on 01 October 2014

Tags: ,

Stemgent has completed the sale of its stem cell reagents and services business to ReproCELL in a cash transaction for approximately $8.5 million.

Stemgent is selling the stem cell reagent and services business in order to focus on expanding its human tissue-based brand, Asterand Biosciences.

Asterand has operated successfully for many years and is a leading global provider of high quality, well characterized human tissue and human tissue-based research services which support drug discovery and development and biomarker development and validation.

Concurrent with the sale, the Company name was changed to Asterand Biosciences, Inc.

For further deal information visit Current Agreements (subscription required)

Related

Report: Regenerative Medicine and Stem Cells Partnering Terms and Agreements

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply